LOW-DOSE KETOCONAZOLE ATTENUATES SERUM ANDROGEN LEVELS IN PATIENTS WITH POLYCYSTIC-OVARY-SYNDROME AND INHIBITS OVARIAN STEROIDOGENESIS IN-VITRO

被引:0
|
作者
GAL, M [1 ]
ORLY, J [1 ]
BARR, I [1 ]
ALGUR, N [1 ]
BOLDES, R [1 ]
DIAMANT, YZ [1 ]
机构
[1] HEBREW UNIV JERUSALEM,SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,JERUSALEM,ISRAEL
关键词
KETOCONAZOLE; OVARIAN STEROIDOGENESIS; P450; CYTOCHROMES; POLYCYSTIC OVARY SYNDROME; HYPERANDROGENISM; FEMALE;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To investigate the effects of a low-dose ketoconazole on ovarian steroidogenesis and on serum androgen levels in polycystic ovary syndrome (PCOS). Design: In vitro, human granulosa-luteal cells were incubated with ketoconazole and radiolabeled steroid substrates, to follow their metabolic fate by thin-layer chromatography analysis. In vivo, normally cycling women (n = 7) in their luteal phase were administered one tablet of 200 mg ketoconazole at 8 A.M. Serum steroid levels, sampled basally and at 12 P.M., 4 P.M., and 8 A.M. the next morning, were compared with untreated control group (n = 7) values. Polycystic ovary syndrome women (n = 11) were similarly administered ketoconazole 6 to 10 days after occurence of spontaneous menses. Adrenal origin of hyperandrogenemia was excluded by stimulation with ACTH and a normal basal DHEAS. The steroid diurnal variation was determined in the same patients a day before treatment. Results: In vitro, ketoconazole selectively inhibited the key steroidogenic cytochromes, namely P450(scc), P450(17 alpha), and P450(arom) (IC50 = 0.5 to 1.0 mu g/mL). In vivo, in the luteal phase, ketoconazole transiently decreased serum values (mean +/- SE) of E(2) (19.2% +/- 2.1%) and P (38.3% +/- 8.5%) within 4 to 8 hours. The same low-dose ketoconazole, administered to PCOS women, decreased serum values of androstenedione (17.6% +/- 4.7%), T (24.6% +/- 7.6%), and free T (30.7% +/- 7.7%). In contrast, 17 alpha-hydroxyprogesterone increased concomitantly (78.5% +/- 10.8%), suggesting a greater suppressibility of the P450(17 alpha) lyase activity. The E(2) levels in PCOS patients were slightly elevated (29.1% +/- 5.6%), resulting in a 1.7- to 2.3-fold increase of the E(2):T ratio. Conclusions: These findings suggest that a low-dose ketoconazole may facilitate a decreased intraovarian T:E(2) ratio, which may prove favorable for follicular maturation in PCOS.
引用
收藏
页码:823 / 832
页数:10
相关论文
共 50 条
  • [21] The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome
    M. Yilmaz
    A. Biri
    A. Karakoç
    F. Törüner
    B. Bingöl
    N. Çakir
    B. Tiras
    G. Ayvaz
    M. Arslan
    Journal of Endocrinological Investigation, 2005, 28 : 1003 - 1008
  • [22] The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome
    Yilmaz, M
    Biri, A
    Karakoç, A
    Törüner, F
    Bingöl, B
    Çakir, N
    Tiras, B
    Ayvaz, G
    Arslan, M
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2005, 28 (11) : 1003 - 1008
  • [23] Influencing factors and effects of low oocyte retrieval in patients with polycystic ovary syndrome undergoing in-vitro fertilization
    Yin, Huiqun
    Zhu, Jie
    Wang, Cunli
    Luan, Kang
    Wu, Yan
    Ni, Feng
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2025, 304 : 97 - 103
  • [24] Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test
    Rosenfield, Robert L.
    Mortensen, Monica
    Wroblewski, Kristen
    Littlejohn, Elizabeth
    Ehrmann, David A.
    HUMAN REPRODUCTION, 2011, 26 (11) : 3138 - 3146
  • [25] Granulocyte colony-stimulating factor: A relation between serum and follicular fluid levels and in-vitro fertilization outcome in patients with polycystic ovary syndrome
    Kahyaoglu, Inci
    Yilmaz, Nafiye
    Timur, Hakan
    Inal, Hasan Ali
    Erkaya, Salim
    CYTOKINE, 2015, 74 (01) : 113 - 116
  • [26] THE EFFECTS OF GONADOTROPIN-RELEASING-HORMONE AGONIST ON FOLLICULAR DEVELOPMENT IN PATIENTS WITH POLYCYSTIC-OVARY-SYNDROME IN AN IN-VITRO FERTILIZATION AND EMBRYO-TRANSFER PROGRAM
    GERSAK, K
    MEDENVRTOVEC, H
    TOMAZEVIC, T
    HUMAN REPRODUCTION, 1994, 9 (09) : 1596 - 1599
  • [27] ACUTE CHOLINERGIC BLOCKADE WITH LOW-DOSE PIRENZEPINE (PIR) REDUCES INSULIN AND GLUCOSE RESPONSES TO A MIXED MEAL IN OBESE WOMEN WITH THE POLYCYSTIC-OVARY-SYNDROME (PCOS)
    PREMAWARDHANA, LDKE
    ISMAIL, IS
    PETERS, JR
    SCANLON, MF
    JOURNAL OF ENDOCRINOLOGY, 1992, 135 : P81 - P81
  • [28] Low-dose ovulation induction with urinary gonadotropins or recombinant follicle stimulating hormone in patients with polycystic ovary syndrome
    Szilágyi, A
    Bártfai, G
    Mánfai, A
    Koloszár, S
    Pál, A
    Szabó, I
    GYNECOLOGICAL ENDOCRINOLOGY, 2004, 18 (01) : 17 - 22
  • [29] Selective cut-back protocol for in-vitro fertilization (IVF) ovarian stimulation in patients with polycystic ovary syndrome (PCOS).
    Bush, M. R.
    Swanson, M. S.
    Stephan, S.
    Albrecht, B. H.
    FERTILITY AND STERILITY, 2007, 88 : S293 - S293
  • [30] Cumulative live birth rates of oocyte in-vitro maturation and controlled ovarian stimulation in infertile patients with polycystic ovary syndrome
    Segers, I.
    Santos-Ribeiro, S.
    Mostinckx, L.
    Tournaye, H.
    Verheyen, G.
    De Vos, M.
    HUMAN REPRODUCTION, 2020, 35 : 1417 - 1417